REVOLUTION Medicines(RVMDW)

Focus: REVOLUTION Medicines is a publicly-traded oncology-focused biotech developing small-molecule RAS pathway inhibitors and targeted cancer therapies across multiple solid tumor indications. The company is rapidly scaling commercial infrastructure ahead of potential Phase 3 readouts in pancreatic and colorectal cancer.

Oncology Neurology Gastroenterology Respiratory

Profile data last refreshed 53m ago · AI intelligence enriched 1mo ago

Funding Stage

PUBLIC

Total Funding

$1B

Open Jobs

319+347 this month

Hot — 484 jobs added in 30d

Net +347 (484 new, 137 removed). Aggressive expansion phase.

Should You Work at REVOLUTION Medicines?

AI assessment

REVOLUTION is a high-risk, high-reward mid-cap biotech bet: bet-the-company phase on RAS oncology programs, strong cash position, and credible commercial planning, but dependent entirely on Phase 3 readouts in 2026–2027.

Why Work Here

Multiple Phase 3 programs (daraxonrasib in pancreatic cancer, RMC-6236 in colorectal and pancreatic cancer, zoldonrasib in pancreatic cancer) with near-term catalysts and commercial upside

Data completeness

7/9 — Strong

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$12M

Products & Portfolio (1)

RASONQUE

daraxonrasib

Launch

ORAL · TABLET

2026

LOE: 2042

Pipeline & Clinical Trials

Help build intelligence for REVOLUTION Medicines

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Aggressive hiring of 200 open roles, with 75 commercial positions signaling confidence in imminent approvals and market launch readiness

Public company status ($696M cash, $12M FY2025 revenue) with access to capital markets and established governance, reducing biotech restructuring risk

Watch Out For

Pre-commercial stage with only $12M FY2025 revenue and 3654% R&D intensity—heavy cash burn ($436M net loss FY2025) means execution risk is critical; failure to advance Phase 3 programs or clinical setbacks could trigger restructuring
Founded only in 2023 with no marketed products and minimal clinical publications (5 total)—limited track record of regulatory success or manufacturing scale

Generated by Claude from REVOLUTION Medicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Clinical Trials (1)

NCT06040541Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Phase 1

RMC-5552

Glioblastoma

PHASE_1

Clinical Trials (1)

NCT05557292RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma

Phase 1

RMC-4630

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT03634982Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1

RMC-6291

Non-Small Cell Lung Cancer (NSCLC)

PHASE_1

Clinical Trials (1)

NCT05462717Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Phase 1

RMC-5552

Solid Tumors

PHASE_1

Clinical Trials (1)

NCT04774952Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1

RMC-5127

Non-small Cell Lung Cancer (NSCLC)

PHASE_1

Clinical Trials (1)

NCT07349537Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Phase 1

Vociprotafib

Metastatic Neoplasm

PHASE_1_2

Clinical Trials (1)

NCT04418661Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies

Phase 1/2

RMC-6291

Non-Small Cell Lung Cancer, NSCLC

PHASE_1_2

Clinical Trials (1)

NCT06162221Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Phase 1/2

RMC-6236

Colorectal Cancer

PHASE_1_2

Clinical Trials (3)

NCT07805954Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

Phase 3

NCT06445062Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1/2

NCT07573215Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

N/A

Elironrasib

Non-Small Cell Lung Cancer (NSCLC)

PHASE_1_2

Clinical Trials (1)

NCT06128551Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Phase 1/2

RMC-6236

Non-small Cell Lung Cancer (NSCLC)

PHASE_1_2

Clinical Trials (1)

NCT05379985Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Phase 1/2

Daraxonrasib

Advanced Solid Tumors

PHASE_1_2

Clinical Trials (1)

NCT07397338Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1/2

RMC-4630

Solid Tumor

PHASE_1_2

Clinical Trials (1)

NCT03989115Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Phase 1/2

TNG462

PDAC

PHASE_1_2

Clinical Trials (1)

NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Phase 1/2

RMC-4630

Non-Small Cell Lung Cancer

PHASE_2

Clinical Trials (1)

NCT05054725Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Phase 2

RMC-6236

Pancreatic Cancer

PHASE_3

Clinical Trials (1)

NCT06625320Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3

daraxonrasib

Pancreatic Cancer

PHASE_3

Clinical Trials (1)

NCT07252232Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3

daraxonrasib

NSCLC (Non-small Cell Lung Cancer)

PHASE_3

Clinical Trials (5)

NCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 3

NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Phase 3

NCT07793253Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Phase 2

+2 more

Zoldonrasib

Pancreatic Cancer

Phase 3

Clinical Trials (2)

NCT07777822Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Phase 3

NCT07621718Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Phase 3

Interview Prep Quick Facts

Founded: 2023

Portfolio: 1 approved product, 26 clinical trials

Top TAs: Oncology

Publications: 31 in PubMed

SEC Filings: 2 available

Open Roles: 319 active jobs

Portfolio Health

Launch1 (100%)

1 total products

Therapeutic Area Focus

Oncology

26 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$12M67%

R&D Spend

$423M(3654%)67%

Net Income

-$436M

Hiring Trend

Actively Hiring

319

Open Roles

+49

Added

-14

Filled/Removed

Based on last 4 crawl cycles

Research Publications(10)

Recent peer-reviewed publications with author affiliations at this company

Distinct ERK and PI3K dependencies mediate a heterogeneous response to RAS(ON) inhibition in KRAS-mutant colorectal cancer.

Cell reports

2026

PMID:42319820

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

The New England journal of medicine

Showing 5 of 10 publications

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

REVOLUTION Medicines(RVMDW)

Should You Work at REVOLUTION Medicines?

Why Work Here

Products & Portfolio (1)

Pipeline & Clinical Trials

Watch Out For

Recent News · REVOLUTION Medicines(10)

Open Jobs (319)

Talent Acquisition Coordination Manager

Senior Safety Scientist I

Senior Manager, Global Patient Safety Operations

Vice President, Tax

Senior Manager, Regulatory Affairs Labeling

Associate Director, Project Management, Patient Support Program Operations

Senior Director, Clinical Operations

Associate Director, US Pricing Contract Operations & Rebate Processing

Director, Organizational Development Partner

Senior Research Associate, Biophysics, Mechanism of Action

Director, Global Corporate Learning Management Systems

Director, US Medical Affairs, NSCLC

Director, US Medical Affairs, PDAC

Senior Director, Head of Structural Biology

Senior Clinical Documentation Specialist

Regional Insights and Engagement Director, PDAC, Southeast

Associate Director, Portfolio Management

Associate Director, Data Standards and EDC Programming

Director, GxP Quality Governance and Partnerships

Associate Director, Access Strategy and Marketing

Associate Director, Field Reimbursement

National Account Director, Community Oncology

Director, Access Strategy & Marketing

Associate Director, US Field Analytics, Lung

Director, Market Access Analytics

Financials (FY2025)

Hiring Trend

Research Publications(10)